International Society for Pediatric and Adolescent Diabetes (ISPAD) has developed specific guidelines for the assessment and monitoring of glycemic control in children and adolescents with diabetes. 1 While ketone levels ≤0.6 mmol/L are considered normal, elevated levels >0.6 mmol/L indicate mild ketosis, >1.5 mmol/L represents the level at which there is a high risk of progression to ketoacidosis, and ketoacidosis is imminent with ketone levels >3.0 mmol/L. 1 DKA is a major health concern in children with T1D and is associated with significant morbidity and mortality. 2, 3 Despite this concern, there is a lack of systematic collection of the rate of ketosis in pediatric populations with T1D.
Unchecked, ketosis will progress to DKA. In children with established diabetes, 4.9% to 7.1% of children and adolescents experienced at least one episode of DKA in the previous year. 4, 5 DKA in established diabetes is a preventable condition, and education on "sick-day rules" is routinely provided to all patients and their families. This emphasizes the importance of frequent checking for ketones and glucose, and administering additional insulin as required.
Nonetheless, the relatively high rates of DKA, particularly in adolescents, remain a significant public health challenge, and DKA remains the commonest cause of death in pediatric T1D. 6 Glycemic control can be affected by the pharmacokinetic and pharmacodynamic properties of insulins, with variable time-action profiles leading to variability in plasma glucose (PG). The aim of insulin treatment is to emulate physiological insulin secretion as closely as possible. Insulin degludec (degludec) is a new-generation basal insulin with a flat pharmacokinetic profile and a long duration of action.
Degludec has been co-formulated with insulin aspart (IAsp) in a novel co-formulation of 70% degludec and 30% IAsp (IDegAsp) in a single injection. 7 When dosed once daily (OD) with the main meal, this coformulation provides insulin coverage for the meal via the IAsp component, and sustained basal insulin coverage for over 24 hours via the degludec component. 7 This treatment potentially allows delivery of basal-bolus therapy with fewer insulin injections, and may be of particular utility in patients with needle phobia, or who are poorly adherent to insulin therapy. 2 | METHODS
| Trial design and participants
In accordance with local regulations, the protocol, protocol amendments, consent form, child assent form, subject information sheet and all other information provided to participants and parents/legal representatives were approved by the relevant health authorities and independent ethics committees/institutional review boards, and the trials were conducted according to the Declaration Figure S1 ).
| Assessments
In both Studies 1 and 2, self-measured blood glucose (SMBG) measurements were performed with capillary blood automatically calibrated to plasma-equivalent glucose values, using centrally supplied glucose monitors able to capture both blood glucose and blood 
| Safety assessments
All patients receiving at least one dose of trial product were included in the safety analysis set.
Safety measures included all adverse events (AEs) and serious adverse events (SAEs).
| Statistical analysis
Analyses of efficacy endpoints were based on the full analysis set.
Estimated mean treatment differences (or rate ratios) were presented together with two-sided 95% confidence intervals.
Change from baseline in HbA1c was analyzed as previously described. 8, 9 The number of hyperglycemic episodes (>14 mmol/L; 252 mg/dL) and episodes of ketosis are presented using descriptive statistics. The number of events (hyperglycemic episodes and episodes of ketosis) was analyzed using negative binomial regression using a log link and the logarithm of the exposure time (100 years) as offset. The model included treatment, sex, region, and age group as fixed effects. 
| Hyperglycemia with and without symptoms
The hyperglycemic episodes with and without symptoms for patients with PG levels >14 mmol/L (252 mg/dL) are shown in In Study 1, 62.3% of patients in the IDet treatment arm were using IDet BID at the end of the core phase and 64.0% were using
IDet BID at the end of the extension phase; in Study 2, 54.2% of patients in the IDet treatment arm were using IDet BID. All patients in the IDegAsp treatment arms received IDegAsp OD. (Table 1) .
| Episodes of ketosis
In Study 1, recurrent ketosis (defined here as more than one episode during the 26-week core or extension phases of the study) occurred in 10.3% (n = 18) of patients in the degludec arm vs 15.4%
(n = 27) of patients in the IDet arm. In Study 2, recurrent ketosis occurred in 1.1% (n = 2) patients in both the degludec and IDet arms. Figure 1 ). The beneficial effect of degludec/IDegAsp was more marked at higher levels of ketosis.
Analysis of the rate of episodes of ketosis by age group (1-5, 6-11, and 12-17 years) showed that episodes of ketosis (>1.5 mmol/L)
were highest in children aged 1-5 years in both studies (Table 3) .
Rates of ketosis were consistently lower with degludec/IDegAsp vs
IDet across age groups. The rates of ketosis with symptoms were numerically lower with degludec and IDegAsp compared with IDet in both trials (Table 4 ).
| Adverse events
The majority of reported AEs for both groups in Studies 1 and 2 were mild or moderate in severity and considered unlikely to be related to trial product. AEs are reported in detail in Thalange et al. 8 and Battelino et al. Insulin therapy is the mainstay of treatment in T1D and may be intensified in an attempt to achieve tighter glycemic control. However, intensification of insulin therapy is associated with an increased risk of hypoglycemia. In contrast, degludec, with its flat pharmacokinetic profile and long duration of action, offers the potential to improve glycemic control by providing sustained basal insulin coverage for over 24 hours.
DKA is associated with significant morbidity and mortality in children with T1D. 2, 3 Despite the major health concerns of DKA, there is a lack of systematic collection of data on ketosis in children with T1D While data on compliance are not available for these studies, it can be assumed that the patients in these rigorously monitored clinical These data demonstrate the potential of degludec/IDegAsp, compared with IDet, to reduce the rate of ketosis and metabolic decompensation in children with T1D. Furthermore, these data highlight the ongoing need for patients to understand the importance of avoiding ketosis, and consequently DKA-the commonest cause of death in children with T1D.
